# Guy E. Boeckxstaens
Guy E. Boeckxstaens (also published as Guy Boeckxstaens and G. E. Boeckxstaens; born 1963) is a Belgian physician-scientist in gastroenterology, working in neurogastroenterology, the study of the nervous control of the digestive tract, and in the immunology of the gut wall. He is a full professor of medicine at [KU Leuven](https://www.edgepedia.org/ku-leuven), where he leads the Laboratory for Intestinal Neuro-Immune Interaction within the Translational Research Center for Gastrointestinal Disorders (TARGID).[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) According to Orphanet, he is known for coordinating the European Achalasia Trial, a randomized comparison of the two standard treatments for achalasia published in the New England Journal of Medicine in 2011, and for work showing that the gut's macrophages are a self-maintaining population essential to intestinal function.[3](https://doi.org/10.1056/nejmoa1010502) • [4](http://www.cell.com/article/S0092867418309760/pdf)
| Fact | Detail |
|---|---|
| Field | Gastroenterology; neurogastroenterology and neuro-immune interaction[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) |
| Born | 1963[5](https://www.uva.nl/content/nieuws/hoogleraarsbenoemingen/2006/03/dhr-dr-g-e-e-boeckxstaens.html) |
| Training | MD 1987 and PhD 1991, University of Antwerp; gastroenterology qualification 1994[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [6](https://orcid.org/0000-0001-8267-5797) |
| Current role | Full professor, KU Leuven, and gastroenterologist at University Hospital Leuven, both since 2007; leads the Intestinal Neuro-Immune Interaction laboratory (TARGID)[6](https://orcid.org/0000-0001-8267-5797) • [2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) |
| Signature work | European Achalasia Trial (NEJM, 2011); self-maintaining gut macrophages (Cell, 2018)[3](https://doi.org/10.1056/nejmoa1010502) • [4](http://www.cell.com/article/S0092867418309760/pdf) |
| Major funding | ERC Advanced Grants in 2013 (CHOLSTIM) and 2019 (NEUMACS)[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) |
| Leadership roles | Became Chair of the Rome IV committee on Fundamentals of Neurogastroenterology; Associate Editor of Gut[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) |
## Career and training
Training. According to his KU Leuven biography, Boeckxstaens studied medicine at the [University of Antwerp](https://www.edgepedia.org/university-of-antwerp), receiving his medical degree in 1987 and completing a PhD there in 1991, while ORCID dates the MD from 1980 to 1987 and the doctorate from 1987 to 1991.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [6](https://orcid.org/0000-0001-8267-5797) His PhD was in neurogastroenterology, and during it his group found that nitric oxide is the main neurotransmitter of the inhibitory non-adrenergic non-cholinergic (NANC) nerves of the gut, a result published in Nature in 1990.[7](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens) He completed clinical training in internal medicine and gastroenterology in 1994, followed by six months of additional training in 1995 in Adelaide, Australia.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [6](https://orcid.org/0000-0001-8267-5797) • [7](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens)
**Amsterdam.** In 1994 he took a staff position in the Department of Gastroenterology and [Hepatology](https://www.edgepedia.org/hepatology) at the Academic Medical Center in Amsterdam, where he headed the Motility Center from 1994; ORCID records the AMC employment as running from 1994 to 2011.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [5](https://www.uva.nl/content/nieuws/hoogleraarsbenoemingen/2006/03/dhr-dr-g-e-e-boeckxstaens.html) • [6](https://orcid.org/0000-0001-8267-5797) In 2005 he became Professor of Neurogastroenterology at the Academic Medical Center and the [University of Amsterdam](https://www.edgepedia.org/university-of-amsterdam), co-chair of the gastroenterology department and head of gastrointestinal research.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) During his Amsterdam years his group reported a second formative finding: the vagus nerve modulates the intestinal immune system, published in Nature Immunology in 2005.[7](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens)
**Leuven.** In 2007 he obtained an Odysseus grant and returned to Belgium as a full professor of medicine at KU Leuven and a gastroenterologist in the gastroenterology division of University Hospital Leuven; he has held both positions since.[7](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens) • [6](https://orcid.org/0000-0001-8267-5797) According to the Laboratory for Intestinal Neuro-Immune Interaction's page at KU Leuven, he leads the laboratory within TARGID, in the Department of Clinical and Experimental Medicine, and is a member of the LISCO institute for single-cell omics.[2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) • [8](https://www.kuleuven.be/wieiswie/en/person/u0054713) He received European Research Council Advanced Grants in 2013 and 2019: CHOLSTIM, on cholinergic modulation of resident intestinal macrophages, and NEUMACS, on macrophages in neurodegenerative disorders of the intestine and the neuro-immune synapse.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens) • [2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) He became Chair of the Rome IV committee on Fundamentals of Neurogastroenterology, became Associate Editor of Gut, and joined the editorial board of Neurogastroenterology.[1](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens)
## Representative work
**Pneumatic dilation versus Heller myotomy (NEJM, 2011).** As coordinator of the European Achalasia Trial, Boeckxstaens led a multicenter randomized study that assigned 201 patients with newly diagnosed idiopathic achalasia to graded pneumatic dilation (95 patients) or laparoscopic [Heller myotomy](https://www.edgepedia.org/heller-myotomy) (106), with a mean follow-up of 43 months.[3](https://doi.org/10.1056/nejmoa1010502) Therapeutic success with pneumatic dilation was 90% after one year and 86% after two years, against 93% and 90% for surgery (P=0.46); esophageal perforation occurred in 4% of dilated patients and mucosal tears in 12% of surgical patients.[3](https://doi.org/10.1056/nejmoa1010502)
**Self-maintaining gut macrophages (Cell, 2018).** According to *Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis* (Cell, 2018), with Boeckxstaens as corresponding author, the study identified a population of intestinal macrophages, arising from both embryonic precursors and adult bone marrow-derived monocytes, that maintains itself throughout adulthood, against the then-current view that short-lived monocytes continuously replace the gut's macrophages.[4](http://www.cell.com/article/S0092867418309760/pdf) • [9](https://lirias.kuleuven.be/cv?Username=u0054713) Depleting these cells caused abnormalities in the submucosal vasculature and loss of enteric neurons, producing vascular leakage, impaired secretion, and reduced intestinal motility.[4](http://www.cell.com/article/S0092867418309760/pdf) His review *Achalasia* in [The Lancet](https://www.edgepedia.org/the-lancet) surveys the disorder at the center of his clinical research.[10](https://doi.org/10.1016/s0140-6736(13)60651-0)
## Achalasia: from the European trial to changing practice
Achalasia is a rare disorder in which the lower esophageal sphincter fails to relax, obstructing the passage of food. The 2011 trial's five-year follow-up, published in Gut in 2016, reported success in 84% of surgical and 82% of dilated patients (p=0.92), with repeat dilation needed in 25% of the dilation group, and concluded that either treatment can be proposed as initial therapy.[11](https://gut.bmj.com/content/65/5/732) The European Society of Gastrointestinal Endoscopy guideline recommends a graded pneumatic dilation protocol, starting at 30 mm and proceeding through 35 mm to 40 mm when relief is insufficient.[12](https://lirias.kuleuven.be/3039203?limo=0) Orphanet records him as principal investigator and coordinator of the completed trial.[13](https://www.orpha.net/en/institutions/professional/88311)
Subsequent practice evolved around peroral endoscopic myotomy (POEM), an endoscopic alternative. A 2019 randomized trial of 221 patients found clinical success at two years in 83.0% of POEM and 81.7% of Heller myotomy patients, meeting noninferiority, but reflux esophagitis in 57% of POEM patients at three months versus 20% after surgery.[14](https://www.nejm.org/doi/full/10.1056/NEJMoa1905380) A five-year comparison of POEM with pneumatic dilation in treatment-naive patients reported success of 81% versus 40%, with proton-pump inhibitor use in remission of 46% versus 13%.[15](https://doi.org/10.1016/s2468-1253(22)00300-4)
## Gut macrophages and intestinal homeostasis
His laboratory studies the two-way signaling between intestinal immune cells, chiefly macrophages and mast cells, and the enteric and extrinsic nerves, in irritable bowel syndrome, postoperative ileus, colitis, food allergy, and achalasia.[2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) The 2018 Cell finding showed that macrophages are not transient visitors but long-lived residents, and that depleting them leads to loss of enteric neurons, vascular leakage, impaired secretion, and reduced intestinal motility.[4](http://www.cell.com/article/S0092867418309760/pdf) The vagal work of 2005 and the CHOLSTIM and NEUMACS grants pursue the same axis from the nervous side.[7](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens) • [2](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm) A review on intestinal neuron-associated macrophages in Nature Immunology in 2025 shows the line of work continues through the period covered here.[16](https://doi.org/10.1038/s41590-025-02150-6)
## References
1. [Contact/Bio Guy Boeckxstaens, KU Leuven](https://gbiomed.kuleuven.be/english/research/50000625/50000628/contact-bio-guy-boeckxstaens)
2. [Intestinal neuroimmune interaction, Laboratory for Intestinal Neuro-Immune Interaction, TARGID, KU Leuven](https://gbiomed.kuleuven.be/english/research/50000625/50000628/site/neuroimmune.htm)
3. [Pneumatic Dilation versus Laparoscopic Heller's Myotomy for Idiopathic Achalasia (NEJM, 2011)](https://doi.org/10.1056/nejmoa1010502)
4. [Self-Maintaining Gut Macrophages Are Essential for Intestinal Homeostasis (Cell, 2018)](http://www.cell.com/article/S0092867418309760/pdf)
5. [Dhr. dr. G.E.E. Boeckxstaens, Universiteit van Amsterdam](https://www.uva.nl/content/nieuws/hoogleraarsbenoemingen/2006/03/dhr-dr-g-e-e-boeckxstaens.html)
6. [Guy Boeckxstaens (0000-0001-8267-5797), ORCID](https://orcid.org/0000-0001-8267-5797)
7. [Guy E. E. Boeckxstaens, Fondazione Menarini speaker biography](https://fondazione-menarini.com/en/courses-and-events/speaker.html/guy-e-e-boeckxstaens)
8. [Guy Boeckxstaens, KU Leuven who's who](https://www.kuleuven.be/wieiswie/en/person/u0054713)
9. [KU Leuven Lirias bibliography](https://lirias.kuleuven.be/cv?Username=u0054713)
10. https://doi.org/10.1016/s0140-6736(13)60651-0
11. [Long-term results of the European achalasia trial (Gut, 2016)](https://gut.bmj.com/content/65/5/732)
12. [Endoscopic management of gastrointestinal motility disorders, ESGE Guideline](https://lirias.kuleuven.be/3039203?limo=0)
13. [Orphanet: Pr G.E.E. Boeckxstaens](https://www.orpha.net/en/institutions/professional/88311)
14. [Endoscopic or Surgical Myotomy in Patients with Idiopathic Achalasia (NEJM, 2019)](https://www.nejm.org/doi/full/10.1056/NEJMoa1905380)
15. https://doi.org/10.1016/s2468-1253(22)00300-4
16. [Intestinal neuron-associated macrophages in health and disease (Nature Immunology, 2025)](https://doi.org/10.1038/s41590-025-02150-6)
17. [Comparative Effectiveness of POEM, LHM, Pneumatic Dilation, and Botulinum Toxin for Achalasia](https://doi.org/10.1097/mcg.0000000000002373)
18. [Is POEM more effective than pneumatic dilation and Heller myotomy? (Surgical Endoscopy)](https://link.springer.com/article/10.1007/s00464-021-08353-w)
19. [POEM compared to LHM and pneumatic dilation in the treatment of achalasia (Diseases of the Esophagus, 2023)](https://doi.org/10.1093/dote/doad055)
---
*Topic: Encyclopedia › Life and health › Life and health scientists › Medical and health researchers › Gastroenterology and hepatology researchers › Luminal gastroenterologists › Esophageal and gastric researchers*
*Initially written Sep 20, 2026 · Reviewed: Sep 25, 2026 · Edited: Sep 25, 2026; Oct 11, 2026 · Last review: Sep 25, 2026*
*Copyright 2026 EdgeChat AI, a subsidiary of Biostate AI.*
License: Edgepedia Community License 1.0, https://www.edgepedia.org/edgepedia/license